{"product_id":"drug-metabolism-and-pharmacokinetics-isbn-9781394300129","title":"Drug Metabolism and Pharmacokinetics","description":"\u003cp\u003e\u003cb\u003ePractical, state-of-the-art pharmacokinetic research methods, ideas, advancements, applications, and strategies\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eDrawing on a wealth of extensive practical experience and theoretical research, \u003ci\u003eDrug Metabolism and Pharmacokinetics\u003c\/i\u003e encapsulates the most recent advancements and illustrative applications in the field. Sixty-eight relatively independent yet interconnected articles are included, each offering a unique perspective and providing in-depth interpretation. Readers can either read systematically or select specific topics of interest from the table of contents. \u003c\/p\u003e\u003cp\u003eBasic concepts, frontier advancements, DMPK research strategies, and technical methods are covered for novel drug modalities and therapeutics in different disease areas. The book encompasses a wide range of application and validation cases for DMPK research, including studies in \u003ci\u003ein vitro \u003c\/i\u003eADME, \u003ci\u003ein vivo \u003c\/i\u003epharmacokinetics, metabolite profiling and identification, radiolabeled ADME, and bioanalysis. Case studies showing the application of topics covered are included throughout, along with valuable insights into problem-solving and critical thinking. \u003c\/p\u003e\u003cp\u003eWritten by a team of scientists specializing in DMPK research from the DMPK Department of WuXi AppTec, \u003ci\u003eDrug Metabolism and Pharmacokinetics\u003c\/i\u003e discusses sample topics including: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eADME properties, metabolite identification, and bioanalytical strategies for oligonucleotide drugs\u003c\/li\u003e\n\u003cli\u003eStrategies and challenges in the determination of drug-to-antibody ratio (DAR) values of antibody-drug conjugates (ADCs)\u003c\/li\u003e\n\u003cli\u003eBreaking barriers in CNS drug development with intrathecal and intracerebroventricular administration\u003c\/li\u003e\n\u003cli\u003eApplication and detection techniques of biomarkers in drug development\u003c\/li\u003e\n\u003cli\u003eFlux dialysis method for assessing plasma protein binding of high protein-binding drugs\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003e\u003ci\u003eDrug Metabolism and Pharmacokinetics\u003c\/i\u003e is an essential forward-thinking reference on the subject for pharmacy students, pharmaceutical industry researchers, and DMPK scientists, especially those exploring novel drug modalities. \u003c\/p\u003e\u003cp\u003eAbout the Editors ix\u003c\/p\u003e \u003cp\u003ePreface xi\u003c\/p\u003e \u003cp\u003eAcknowledgments xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection I Novel Drug Modalities: Advancements and Their Pharmacokinetic Strategies 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Proteolysis-Targeting Chimeras (PROTACs) 3\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1.1 An Overview of PROTAC Technology and Drug Metabolism and Pharmacokinetic (DMPK) Research Strategies 3\u003c\/p\u003e \u003cp\u003e1.2 Strategies to Improve the Oral Bioavailability of PROTACs 9\u003c\/p\u003e \u003cp\u003e1.3 Research on PROTAC Metabolism: Strategies and Main Approaches 17\u003c\/p\u003e \u003cp\u003e1.4 Metabolic Characteristics and Research Strategies for Metabolite Identification of PROTACs 23\u003c\/p\u003e \u003cp\u003e1.5 Evaluation of Drug-Drug Interactions of PROTACs with Efflux Transporters 40\u003c\/p\u003e \u003cp\u003e1.6 PROTAC Bioanalysis: Challenges and Strategies 44\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Antibody–Drug Conjugates (ADCs) 49\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2.1 General Considerations for Pharmacokinetic Studies of ADCs 49\u003c\/p\u003e \u003cp\u003e2.2 Application of Integrated Bioanalysis in ADC DMPK Studies 53\u003c\/p\u003e \u003cp\u003e2.3 Study Models and Bioanalysis Methods for the Payload-Related Metabolite Identification Studies of ADCs 62\u003c\/p\u003e \u003cp\u003e2.4 Strategies and Challenges in the Determination of Drug-to-Antibody Ratio (DAR) Values for ADCs 67\u003c\/p\u003e \u003cp\u003e2.5 In Vitro Stability of ADCs in Blood Matrices 78\u003c\/p\u003e \u003cp\u003e2.6 Application of Radiolabeling Techniques in ADC Pharmacokinetic Studies 86\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Peptide–Drug Conjugates (PDCs) 95\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction to PDCs and DMPK Research Strategies 95\u003c\/p\u003e \u003cp\u003e3.2 Targeted Release Principle and Metabolite Identification Studies of PDCs 102\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Peptide Drugs 115\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e4.1 Development, Characteristics, and Pharmacokinetic Research Strategies of Peptide Drugs 115\u003c\/p\u003e \u003cp\u003e4.2 Metabolic Characteristics and Optimization Strategies of Peptide Drugs 123\u003c\/p\u003e \u003cp\u003e4.3 Insights into ADME Studies of 37 Approved Therapeutic Peptides: Strategies and Radiolabeling Considerations 132\u003c\/p\u003e \u003cp\u003e4.4 Challenges and Strategies in the Bioanalysis of Peptide Drugs 138\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Oligonucleotide (OLIGO) Drugs 147\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e5.1 Oligonucleotide Drugs: An Introduction and Overview of Pharmacokinetic Strategies 147\u003c\/p\u003e \u003cp\u003e5.2 Delivery Systems of siRNA Drugs and Their Effects on the Pharmacokinetic Profile 152\u003c\/p\u003e \u003cp\u003e5.3 Bioanalytical Strategies for Oligonucleotide Drugs 157\u003c\/p\u003e \u003cp\u003e5.4 Oligonucleotide Drugs: Strategies for Metabolism and Metabolite Profiling and Identification 183\u003c\/p\u003e \u003cp\u003e5.5 ADME Characteristics of Approved siRNA and ASO Drugs 193\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 mRNA-Based Vaccines and Therapeutics 213\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e6.1 What Are mRNA Vaccines and Their Future 213\u003c\/p\u003e \u003cp\u003e6.2 Strategies for Preclinical PK Evaluation of mRNA-Based Therapeutics: mRNA Vaccines, mRNA Therapeutic Drugs, and Novel Excipients 221\u003c\/p\u003e \u003cp\u003e6.3 FDA-Approved mRNA Vaccines: Interpretation of Preclinical Pharmacokinetic (PK) Data 230\u003c\/p\u003e \u003cp\u003e6.4 Application of Integrative Bioanalysis in mRNA Drugs DMPK Research 235\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection II Pharmacokinetic and Metabolism Studies of Therapeutics for Disease Areas 243\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Ophthalmic Drugs 245\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7.1 Ophthalmic Drugs: Preclinical Pharmacokinetic (PK) Profiles and Research Strategies 245\u003c\/p\u003e \u003cp\u003e7.2 In Vitro Methods and Significance of Drug–Melanin Binding 253\u003c\/p\u003e \u003cp\u003e7.3 Preclinical Pharmacokinetic Research of Ophthalmic Drugs: In Vitro and In Vivo Research Methods 259\u003c\/p\u003e \u003cp\u003e7.4 In Vivo Bioanalysis in Ophthalmology: Challenges and Strategies 269\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Respiratory Drugs 275\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8.1 Inhaled Medications: Challenges and Strategies for Preclinical In Vivo Pharmacokinetic Studies 275\u003c\/p\u003e \u003cp\u003e8.2 Chronic Obstructive Pulmonary Disease (COPD): Analysis of PK Profiles of Approved Inhaled Medications 285\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Transdermal and Topical Drugs 291\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e9.1 Preclinical Pharmacokinetic Strategies for Topical and Transdermal Drug Products 291\u003c\/p\u003e \u003cp\u003e9.2 Application of In Vitro Permeation Test (IVPT) for the Development of Transdermal and Topical Drugs 300\u003c\/p\u003e \u003cp\u003e9.3 Evaluation of Transdermal Drugs in In Vivo Pharmacokinetic Studies 308\u003c\/p\u003e \u003cp\u003e9.4 Challenges and Bioanalytical Strategies for Quantitative Detection of In Vivo Biological Samples from Skin Administration 313\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Central Nervous System Drugs 317\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10.1 Overview of Pharmacokinetic Research Strategies for Central Nervous System Drugs 317\u003c\/p\u003e \u003cp\u003e10.2 Application of Microdialysis in Pharmacokinetic Research 329\u003c\/p\u003e \u003cp\u003e10.3 Central Nervous System Drug Development Techniques: Exploration and Application in Large Animal Pharmacokinetics 337\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection III Research Strategies, Methods, and Applications in Pharmacokinetics and Metabolism 343\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 In Vitro ADME 345\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e11.1 Rapid Determination of Lipophilicity: Establishment and Application of Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) 345\u003c\/p\u003e \u003cp\u003e11.2 Plasma Protein Binding Measurement of High Protein-Binding Drugs: Principlesand Advantages of the Flux Dialysis Method 351\u003c\/p\u003e \u003cp\u003e11.3 How to Measure the Metabolic Clearance of Slowly Metabolized Compounds 358\u003c\/p\u003e \u003cp\u003e11.4 Non-P450 Enzyme-Mediated Metabolism and In Vitro Assessment Method 365\u003c\/p\u003e \u003cp\u003e11.5 In Vitro Evaluation of CYP450 Time-Dependent Inhibition (TDI): A Novel Area Under the Curve Shift (AUC Shift) Approach 377\u003c\/p\u003e \u003cp\u003e11.6 Cytochrome P450 Reaction Phenotyping for Four Additional CYPs: Why and How 383\u003c\/p\u003e \u003cp\u003e11.7 Overview of the Application of the Na + -Taurocholate Cotransporting Polypeptide (NTCP) in Drug Development 388\u003c\/p\u003e \u003cp\u003e11.8 The Significance and In Vitro Methods of Lysosomal Trapping in Drug Development 397\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 In Vivo Pharmacokinetics 407\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12.1 Enhancing the Bioavailability of Poorly Soluble Compounds: Strategies for Formulation Optimization in Preclinical Studies 407\u003c\/p\u003e \u003cp\u003e12.2 Self-Emulsifying Drug Delivery System (SEDDS): Enhancing the Oral Absorption of Lipophilic Compounds 414\u003c\/p\u003e \u003cp\u003e12.3 Application of Anesthetics in Rodent Pharmacokinetic Studies 420\u003c\/p\u003e \u003cp\u003e12.4 Application of In Situ Single-Pass Intestinal Perfusion (SPIP) Model in the Study of Intestinal Absorption of Oral Drugs 428\u003c\/p\u003e \u003cp\u003e12.5 Application of Liver Biopsy in Preclinical Pharmacokinetic Studies 436\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Metabolite Profiling and Identification 441\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e13.1 High-Throughput Identification of Drug Metabolic Soft Spots for Lead Optimization 441\u003c\/p\u003e \u003cp\u003e13.2 Application of Metabolite Biosynthesis Technology in the Precise Identification of Drug Metabolite Structures 449\u003c\/p\u003e \u003cp\u003e13.3 Detection of Reactive Metabolites and Its Application in Drug Research and Development 456\u003c\/p\u003e \u003cp\u003e13.4 UGT Enzymes: Metabolite Identification and Toxicity Assessment Strategies 466\u003c\/p\u003e \u003cp\u003e13.5 Insights into the R\u0026amp;D Strategies of Deuterated Drugs from the Drug Metabolism Perspective 472\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Radiolabeled In Vivo ADME Studies 479\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e14.1 Placental Transfer and Milk Excretion Studies Based on Radioactive Tracer Technique 479\u003c\/p\u003e \u003cp\u003e14.2 Visualization of Tissue Distribution: Quantitative Whole-Body Autoradiography (qwba) 486\u003c\/p\u003e \u003cp\u003e14.3 Preclinical and Clinical Research Strategy for Human Radiolabeled Mass Balance Studies 490\u003c\/p\u003e \u003cp\u003e14.4 Key Considerations for Conducting Radiolabeled Human Mass Balance Studies 496\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Bioanalysis 503\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e15.1 Application of High-Throughput Mass Spectrometry in In Vitro ADME 503\u003c\/p\u003e \u003cp\u003e15.2 Application and Detection Techniques of Biomarkers in Drug Development 510\u003c\/p\u003e \u003cp\u003e15.3 Analysis and Detection Strategies of Liposome Drugs in Biological Samples 516\u003c\/p\u003e \u003cp\u003e15.4 DMPK Research Strategies of Chiral Drugs Based on UPCC-MS\/MS and UPLC-MS\/MS Dual Analytical Platforms 523\u003c\/p\u003e \u003cp\u003e15.5 Integrated Qualitative and Quantitative Bioanalysis of Intact Protein with High-Resolution Mass Spectrometry 530\u003c\/p\u003e \u003cp\u003e15.6 Nanobodies: Kinetics and Bioanalytical Strategies 540\u003c\/p\u003e \u003cp\u003eIndex 549\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eLiang Shen, PhD,\u003c\/b\u003e is the head of DMPK at WuXi AppTec.   \u003c\/p\u003e\u003cp\u003e\u003cb\u003ePractical, state-of-the-art pharmacokinetic research methods, ideas, advancements, applications, and strategies\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eDrawing on a wealth of extensive practical experience and theoretical research, \u003ci\u003eDrug Metabolism and Pharmacokinetics\u003c\/i\u003e encapsulates the most recent advancements and illustrative applications in the field. Sixty-eight relatively independent yet interconnected articles are included, each offering a unique perspective and providing in-depth interpretation. Readers can either read systematically or select specific topics of interest from the table of contents. \u003c\/p\u003e\u003cp\u003eBasic concepts, frontier advancements, DMPK research strategies, and technical methods are covered for novel drug modalities and therapeutics in different disease areas. The book encompasses a wide range of application and validation cases for DMPK research, including studies in \u003ci\u003ein vitro \u003c\/i\u003eADME, \u003ci\u003ein vivo \u003c\/i\u003epharmacokinetics, metabolite profiling and identification, radiolabeled ADME, and bioanalysis. Case studies showing the application of topics covered are included throughout, along with valuable insights into problem-solving and critical thinking. \u003c\/p\u003e\u003cp\u003eWritten by a team of scientists specializing in DMPK research from the DMPK Department of WuXi AppTec, \u003ci\u003eDrug Metabolism and Pharmacokinetics\u003c\/i\u003e discusses sample topics including: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eADME properties, metabolite identification, and bioanalytical strategies for oligonucleotide drugs\u003c\/li\u003e\n\u003cli\u003eStrategies and challenges in the determination of drug-to-antibody ratio (DAR) values of antibody-drug conjugates (ADCs)\u003c\/li\u003e\n\u003cli\u003eBreaking barriers in CNS drug development with intrathecal and intracerebroventricular administration\u003c\/li\u003e\n\u003cli\u003eApplication and detection techniques of biomarkers in drug development\u003c\/li\u003e\n\u003cli\u003eFlux dialysis method for assessing plasma protein binding of high protein-binding drugs\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003e\u003ci\u003eDrug Metabolism and Pharmacokinetics\u003c\/i\u003e is an essential forward-thinking reference on the subject for pharmacy students, pharmaceutical industry researchers, and DMPK scientists, especially those exploring novel drug modalities.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989088190693,"sku":"NP9781394300129","price":285.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781394300129.jpg?v=1761782746","url":"https:\/\/k12savings.com\/products\/drug-metabolism-and-pharmacokinetics-isbn-9781394300129","provider":"K12savings","version":"1.0","type":"link"}